BioCentury

7:00 AM GMT, Jun 6, 2005
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Another VR1 tag team

In the wake of the COX-2 debacle, it's no surprise that Pfizer Inc. is demonstrating an increased interest in alternative mechanisms to treat pain. Last week, PFE announced that it will combine its preclinical vanilloid receptor 1 antagonist program with one from Renovis Inc. Although intellectual property is likely to have been a driver

Read the full 544 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.